TWI624278B - 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物 - Google Patents

使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物 Download PDF

Info

Publication number
TWI624278B
TWI624278B TW103134526A TW103134526A TWI624278B TW I624278 B TWI624278 B TW I624278B TW 103134526 A TW103134526 A TW 103134526A TW 103134526 A TW103134526 A TW 103134526A TW I624278 B TWI624278 B TW I624278B
Authority
TW
Taiwan
Prior art keywords
dexmedetomidine
patient
composition
delivery device
hours
Prior art date
Application number
TW103134526A
Other languages
English (en)
Chinese (zh)
Other versions
TW201521799A (zh
Inventor
阿查拉 朋皮拉帕
艾密特 傑恩
布雷特 伯納
建業 溫
首藤十太郎
Original Assignee
帝國製藥美國股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 帝國製藥美國股份有限公司 filed Critical 帝國製藥美國股份有限公司
Publication of TW201521799A publication Critical patent/TW201521799A/zh
Application granted granted Critical
Publication of TWI624278B publication Critical patent/TWI624278B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW103134526A 2013-10-07 2014-10-03 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物 TWI624278B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361887871P 2013-10-07 2013-10-07
US61/887,871 2013-10-07

Publications (2)

Publication Number Publication Date
TW201521799A TW201521799A (zh) 2015-06-16
TWI624278B true TWI624278B (zh) 2018-05-21

Family

ID=52777130

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103134526A TWI624278B (zh) 2013-10-07 2014-10-03 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物

Country Status (11)

Country Link
US (1) US20150098983A1 (https=)
EP (1) EP3054934B1 (https=)
JP (1) JP6231670B2 (https=)
KR (2) KR101881791B1 (https=)
CN (1) CN105682650B (https=)
CA (1) CA2924190C (https=)
ES (1) ES2983565T3 (https=)
FI (1) FI3054934T3 (https=)
RU (1) RU2648817C2 (https=)
TW (1) TWI624278B (https=)
WO (1) WO2015054063A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924233C (en) * 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
GB201600918D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
EP3813828A4 (en) * 2018-06-27 2022-03-30 Bioxcel Therapeutics, Inc. METHOD OF TREATMENT OF AGITATION WITH DEXMEDETOMIDIN HYDROCHLORIDE
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
WO2020084065A1 (en) * 2018-10-24 2020-04-30 Saniona A/S Transdermal tropane compositions and methods for using the same
CA3135552C (en) * 2019-04-17 2023-09-26 Lts Lohmann Therapie-Systeme Ag Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
JP7495989B2 (ja) 2020-02-14 2024-06-05 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用ナロキソン組成物およびそれを使用するための方法
US20240024289A1 (en) * 2020-10-08 2024-01-25 Bioxcel Therapeutics, Inc. Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
JP2024502082A (ja) * 2021-01-04 2024-01-17 バイオエクセル セラピューティクス，インコーポレイテッド デクスメデトミジン治療レジメン
CN115227638B (zh) * 2022-07-19 2025-03-18 广州新济生物医药研究院有限公司 一种盐酸右美托咪定可溶性微针及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
AU2024253436A1 (en) * 2023-04-04 2025-11-13 Board Of Regents, The University Of Texas System Combinations including methocinnamox

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US20030170195A1 (en) * 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
US20130211351A1 (en) * 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
TW201332546A (zh) * 2012-01-04 2013-08-16 護益仁公司 迪美得托咪汀（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）預混配方

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
CN1188189C (zh) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
MXPA01003310A (es) * 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
TWI341735B (en) * 2003-07-31 2011-05-11 Hisamitsu Pharmaceutical Co Adhesive preparations
EP2062575B1 (en) * 2006-09-11 2012-02-15 Sekisui Chemical Co., Ltd. Adhesive preparation comprising desglymidodrine
EP2286814B1 (en) * 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
US20130072532A1 (en) 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
AU2011331511C1 (en) * 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
WO2013072763A2 (en) * 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
WO2013090278A2 (en) * 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US20030170195A1 (en) * 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
TW201332546A (zh) * 2012-01-04 2013-08-16 護益仁公司 迪美得托咪汀（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）預混配方
US20130211351A1 (en) * 2012-01-31 2013-08-15 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

Also Published As

Publication number Publication date
RU2648817C2 (ru) 2018-03-28
ES2983565T3 (es) 2024-10-23
WO2015054063A1 (en) 2015-04-16
CA2924190A1 (en) 2015-04-16
EP3054934A4 (en) 2017-04-05
KR20180021902A (ko) 2018-03-05
EP3054934A1 (en) 2016-08-17
US20150098983A1 (en) 2015-04-09
JP2016532643A (ja) 2016-10-20
CN105682650A (zh) 2016-06-15
JP6231670B2 (ja) 2017-11-15
KR20160055934A (ko) 2016-05-18
EP3054934B1 (en) 2024-05-22
FI3054934T3 (fi) 2024-07-19
TW201521799A (zh) 2015-06-16
RU2016109632A (ru) 2017-11-15
CA2924190C (en) 2019-07-09
BR112016006200A2 (pt) 2017-08-01
CN105682650B (zh) 2020-09-25
KR101881791B1 (ko) 2018-07-25

Similar Documents

Publication Publication Date Title
TWI624278B (zh) 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
US12527770B2 (en) Methods of managing pain using dexmedetomidine transdermal delivery devices
TWI704933B (zh) 右美托咪啶經皮輸送裝置及使用其之方法
KR101831290B1 (ko) 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
ES2847936T3 (es) Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
US20190175519A1 (en) Naloxone Transdermal Delivery Devices and Methods for Using the Same
BR112016006200B1 (pt) Uso de dispositivo de distribuição transdérmica para tratar síndrome de abstinência
HK40033308A (en) Naloxone transdermal drug-delivery devices and methods for using the same